checkAd

     217  0 Kommentare Evoqua Water Technologies Reports Second Quarter 2023 Results

    Evoqua Water Technologies (NYSE:AQUA), an industry leader in mission-critical water treatment solutions, today reported results for its second quarter ended March 31, 2023.

    Revenue for the second quarter of fiscal year 2023 was $477.8 million, compared to $426.7 million in the prior year period, an increase of 12.0%, or $51.1 million. Organic revenue growth contributed 11.6%, or $49.6 million, driven by favorable price realization and higher volume for products and services across most regions and product lines. Inorganic revenue contributed $5.3 million, primarily related to our acquisition of Smith Engineering in July 2022. Revenue was unfavorably impacted by $3.8 million in the period related to foreign currency translation. Net income for the quarter was $10.6 million, resulting in diluted earnings per share (“EPS”) of $0.08, as compared to net income of $7.4 million and diluted EPS of $0.06 in the prior year period. The increase in net income of 43.2%, or $3.2 million, was favorably impacted by increased revenues and related profit. These benefits were partially offset by increased operating expenses as compared to the prior period, specifically higher legal expenses and other consulting fees associated with various matters and pending transactions, including the proposed merger transaction with Xylem Inc., as well as higher wages and other costs associated with acquisitions and inflation. The Company also recorded a loss of $4.5 million related to the sale of a business and impairment of a long-lived asset. The increased operating costs and losses were somewhat mitigated by non-cash foreign currency translation gains in the current period. Adjusted EBITDA for the quarter was $88.5 million, as compared to $73.2 million in the prior year period, an increase of 20.9%, or $15.3 million. See the “Use of Non-GAAP Measures” section below for additional information regarding adjusted EBITDA.

    “Our second quarter results were quite strong, with improvements across most key financial metrics,” said Ron Keating, Evoqua President and CEO. “Revenues were up 12.0% over the prior year period, broadly distributed across most regions and product lines. Overall market demand continues to be strong, our book to bill ratio was again over 1.0, and ISS backlog grew double digits over the prior year. Adjusted EBITDA and adjusted EBITDA margin achieved record levels for a second fiscal quarter, and we are very pleased with our performance improvements.”

    Mr. Keating continued, “Our price / cost ratio continues to be positive and contributed favorably to margin expansion. We are seeing inflationary pressures stabilizing and material availability across most commodities and components recovering. We expect pricing and availability to continue to improve throughout the second half of our fiscal year. Inventories are up year-over-year supporting strong sales and order book growth but have come down from the prior quarter, leading to an improvement in net working capital. Operating cash flow increased year-over-year and sequentially compared to the prior quarter, driven by EBITDA performance and working capital improvements.”

    Mr. Keating concluded, “We are pleased to have acquired the Texas based industrial water service business from Kemco Systems in February, further strengthening Evoqua's service footprint in the Texas market. Having announced our combination with Xylem in January, 2023 is shaping up to be a transformative year for the company. I appreciate the dedication and focused execution from our entire team as we delivered outstanding first half results.”

    Dissemination of Company Information

    The Company intends to make future announcements regarding developments and financial performance through the Investor Relations section of its website, as well as through press releases, filings with the Securities and Exchange Commission (the “SEC”), conference calls and webcasts. The Company does not incorporate the information contained on, or accessible through, its corporate website into this press release.

    Lesen Sie auch

    About Evoqua Water Technologies

    Evoqua Water Technologies is a leading provider of mission critical water and wastewater treatment solutions, offering a broad portfolio of products, services, and expertise to support industrial, municipal and recreational customers who value water. Evoqua has worked to protect water, the environment and its employees for more than 100 years, earning a reputation for quality, safety and reliability around the world. Headquartered in Pittsburgh, Pennsylvania, the company operates in more than 150 locations across nine countries. Serving more than 38,000 customers and 200,000 installations worldwide, our employees are united by a common purpose: Transforming Water. Enriching Life.

    Non-GAAP Financial Measures

    This press release contains references to adjusted EBITDA, a financial measure that is not calculated and presented in accordance with generally accepted accounting principles in the United States (“GAAP”). This non-GAAP financial measure is provided as additional information for investors. We believe this non-GAAP financial measure is helpful to management and investors in highlighting trends in our operating results and provides greater clarity and comparability period over period to management and our investors regarding the operational impact of long-term strategic decisions relating to capital structure, the tax jurisdictions in which we operate and capital investments. The presentation of this additional information is not meant to be considered in isolation or as a substitute for GAAP measures. For definitions of the non-GAAP financial measures used in this press release and reconciliations to the most directly comparable respective GAAP measures, see the “Use of Non-GAAP Measures” section below.

    Forward-Looking Statements

    This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. You can generally identify forward-looking statements by our use of forward-looking terminology such as “aim,” “anticipate,” “assume,” “believe,” “continue,” “could,” “estimate,” “expect,” “goal,” “intend,” “may,” “might,” “plan,” “progress,” “potential,” “predict,” “projection,” “seek,” “should,” “will,” or “would” or the negative thereof or other variations thereon or comparable terminology. All of these forward-looking statements are based on our current expectations, assumptions, estimates, and projections. While we believe these expectations, assumptions, estimates, and projections are reasonable, such forward-looking statements are only predictions and involve known and unknown risks and uncertainties, many of which are beyond our control. These and other important factors may cause our actual results, performance, or achievements to differ materially from any future results, performance, or achievements expressed or implied by these forward-looking statements, or could affect our share price. Some of the factors that could cause actual results to differ materially from those expressed or implied by the forward-looking statements include, among other things, the failure to complete the proposed transaction with Xylem Inc. (“Xylem”) (the “Merger”) on the anticipated terms and timing, or at all; the failure to obtain stockholder approvals or to satisfy any of the other conditions to the Merger on a timely basis or at all, or other delays in completing the Merger; the failure to obtain necessary regulatory approvals (and the risk that such approvals may result in the imposition of conditions that could adversely affect the combined company or the expected benefits of the Merger); the occurrence of any event, change or other circumstances that could give rise to the right of one or both of the parties to terminate the Company’s merger agreement with Xylem; the possibility that the Merger may be less accretive than expected, or may be dilutive; the possibility that the anticipated benefits of the Merger will not be realized when expected or at all, including as a result of the impact of, or problems arising from, the integration of the two companies or as a result of the strength of the economy and competitive factors in the areas where the Company and Xylem do business; the possibility that the Merger may be more expensive to complete than anticipated, including as a result of unexpected factors or events; diversion of management’s attention from ongoing business operations and opportunities, as a result of the Merger; the risk that stockholder litigation in connection with the Merger may affect the timing or occurrence of the Merger or result in significant costs of defense, indemnification and liability; the effect of the announcement of the Merger on our ability to maintain relationships with customers, suppliers, and other third parties; uncertainty as to the long-term value of Xylem’s common stock; material, freight, and labor inflation, commodity and component availability constraints, and disruptions in global supply chains and transportation services; general global economic and business conditions, including the impacts of rising interest rates, recessionary conditions, geopolitical conflicts, such as the conflict between Russia and Ukraine and tensions between China and the U.S., and the COVID-19 pandemic; our ability to execute projects on budget and on schedule; the potential for us to incur liabilities to customers as a result of warranty claims or failure to meet performance guarantees; our ability to meet our own and our customers’ safety standards; failure to effectively treat emerging contaminants; our ability to continue to develop or acquire new products, services and solutions that allow us to compete successfully in our markets; our ability to implement our growth strategy, including acquisitions, and our ability to identify suitable acquisition targets; our ability to operate or integrate any acquired businesses, assets or product lines profitably; our ability to achieve the expected benefits of our restructuring actions; delays in enactment or repeals of environmental laws and regulations; the potential for us to become subject to claims relating to handling, storage, release or disposal of hazardous materials; our ability to retain our senior management, skilled technical, engineering, sales, and other key personnel and to attract and retain key talent in increasingly competitive labor markets; including as a result of the announcement of the Merger; risks associated with international sales and operations; our ability to adequately protect our intellectual property from third-party infringement; risks related to our contracts with federal, state, and local governments, including risk of termination or modification prior to completion; risks associated with product defects and unanticipated or improper use of our products; our ability to accurately predict the timing of contract awards; risks related to our substantial indebtedness; our increasing dependence on the continuous and reliable operation of our information technology systems; risks related to foreign, federal, state and local environmental, health and safety laws and other applicable laws and regulations and the costs associated therewith; our ability to execute on our strategies related to environmental, social, and governance matters, and achieve related goals and targets, including as a result of evolving standards, laws, regulations, processes, and assumptions, delayed scientific and technological developments, increased costs, and changes in carbon markets; and other risks and uncertainties, including those listed under Part I, Item 1A, “Risk Factors” in our Annual Report on Form 10-K for the fiscal year ended September 30, 2022, as filed with the SEC on November 16, 2022, and in other filings we may make from time to time with the SEC. All statements other than statements of historical fact included in this press release are forward-looking statements, including, but not limited to, certain plans, expectations, goals, projections, and statements about the benefits of the Merger, the expected timing of completion of the Merger, expectations for fiscal year 2023, expectations related to customer demand, our book to bill ratio, pricing initiatives, supply chain challenges, inflation, material and labor availability, and general macroeconomic conditions, and expectations with respect to the integration and performance of our recent acquisitions, including the realization of expected synergies. Any forward-looking statements made in this press release speak only as of the date of this release. Except as required by law, we do not undertake any obligation to update or revise, or to publicly announce any update or revision to, any of the forward-looking statements made herein, whether as a result of new information, future events or otherwise after the date of this release. These forward-looking statements should not be relied upon as representing the Company’s views as of any date subsequent to the date of this release.

    EVOQUA WATER TECHNOLOGIES CORP.

    CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS (Unaudited)

    (In thousands, except per share amounts)

     

     

    Three Months Ended

    March 31,

     

    Six Months Ended

    March 31,

     

     

    2023

     

     

     

    2022

     

     

     

    2023

     

     

     

    2022

     

    Revenue from product sales and services

    $

    477,797

     

     

    $

    426,728

     

     

    $

    913,643

     

     

    $

    792,996

     

    Cost of product sales and services

     

    (325,901

    )

     

     

    (297,842

    )

     

     

    (631,438

    )

     

     

    (553,602

    )

    Gross profit

    $

    151,896

     

     

    $

    128,886

     

     

    $

    282,205

     

     

    $

    239,394

     

    General and administrative expense

     

    (77,758

    )

     

     

    (66,976

    )

     

     

    (141,834

    )

     

     

    (124,805

    )

    Sales and marketing expense

     

    (43,215

    )

     

     

    (39,859

    )

     

     

    (83,601

    )

     

     

    (76,308

    )

    Research and development expense

     

    (4,582

    )

     

     

    (3,751

    )

     

     

    (8,417

    )

     

     

    (7,203

    )

    Total operating expenses

    $

    (125,555

    )

     

    $

    (110,586

    )

     

    $

    (233,852

    )

     

    $

    (208,316

    )

    Other operating (expense) income, net

     

    (2,884

    )

     

     

    1,272

     

     

     

    (1,664

    )

     

     

    2,782

     

    Income before interest expense and income taxes

    $

    23,457

     

     

    $

    19,572

     

     

    $

    46,689

     

     

    $

    33,860

     

    Interest expense

     

    (10,303

    )

     

     

    (9,950

    )

     

     

    (20,377

    )

     

     

    (16,529

    )

    Income before income taxes

    $

    13,154

     

     

    $

    9,622

     

     

    $

    26,312

     

     

    $

    17,331

     

    Income tax expense

     

    (2,522

    )

     

     

    (2,248

    )

     

     

    (6,412

    )

     

     

    (3,869

    )

    Net income

    $

    10,632

     

     

    $

    7,374

     

     

    $

    19,900

     

     

    $

    13,462

     

    Net income attributable to non‑controlling interest

     

     

     

     

    44

     

     

     

     

     

     

    145

     

    Net income attributable to Evoqua Water Technologies Corp.

    $

    10,632

     

     

    $

    7,330

     

     

    $

    19,900

     

     

    $

    13,317

     

    Basic income per common share

    $

    0.09

     

     

    $

    0.06

     

     

    $

    0.16

     

     

    $

    0.11

     

    Diluted income per common share

    $

    0.08

     

     

    $

    0.06

     

     

    $

    0.16

     

     

    $

    0.11

     

    EVOQUA WATER TECHNOLOGIES CORP.

    CONDENSED CONSOLIDATED BALANCE SHEETS

    (In thousands, except per share amounts)

     

     

    (Unaudited)

     

     

     

    March 31,
    2023

     

    September 30,
    2022

    ASSETS

     

     

     

    Current assets

    $

    844,441

     

     

    $

    831,389

     

    Cash and cash equivalents

     

    113,243

     

     

     

    134,005

     

    Receivables, net

     

    303,855

     

     

     

    305,712

     

    Inventories, net

     

    240,713

     

     

     

    229,351

     

    Contract assets

     

    115,461

     

     

     

    102,123

     

    Other current assets

     

    59,547

     

     

     

    60,198

     

    Current assets held for sale

     

    11,622

     

     

     

     

    Property, plant, and equipment, net

     

    414,080

     

     

     

    405,289

     

    Goodwill

     

    468,929

     

     

     

    473,572

     

    Intangible assets, net

     

    299,302

     

     

     

    317,733

     

    Operating lease right-of-use assets, net

     

    56,568

     

     

     

    53,540

     

    Other non-current assets

     

    96,517

     

     

     

    109,340

     

    Non-current assets held for sale

     

    29,733

     

     

     

     

    Total assets

    $

    2,209,570

     

     

    $

    2,190,863

     

    LIABILITIES AND EQUITY

     

     

     

    Current liabilities

    $

    474,491

     

     

    $

    483,716

     

    Accounts payable

     

    216,893

     

     

     

    213,518

     

    Current portion of debt, net of deferred financing fees and discounts

     

    19,376

     

     

     

    17,266

     

    Contract liabilities

     

    75,512

     

     

     

    62,439

     

    Accrued expenses and other liabilities

     

    153,110

     

     

     

    178,272

     

    Other current liabilities

     

    9,113

     

     

     

    12,221

     

    Current liabilities held for sale

     

    487

     

     

     

     

    Non-current liabilities

     

    995,774

     

     

     

    997,054

     

    Long-term debt, net of deferred financing fees and discounts

     

    853,599

     

     

     

    863,534

     

    Obligation under operating leases

     

    45,650

     

     

     

    43,961

     

    Other non-current liabilities

     

    93,822

     

     

     

    89,559

     

    Non-current liabilities held for sale

     

    2,703

     

     

     

     

    Total liabilities

    $

    1,470,265

     

     

    $

    1,480,770

     

    Shareholders’ equity

     

     

     

    Common stock, par value $0.01: authorized 1,000,000 shares; issued 123,944 shares, outstanding 122,280 at March 31, 2023; issued 123,411 shares, outstanding 121,747 at September 30, 2022

    $

    1,240

     

     

    $

    1,235

     

    Treasury stock: 1,664 shares at March 31, 2023 and 1,664 shares at September 30, 2022

     

    (2,837

    )

     

     

    (2,837

    )

    Additional paid-in capital

     

    620,056

     

     

     

    607,748

     

    Retained earnings

     

    80,916

     

     

     

    61,016

     

    Accumulated other comprehensive income, net of tax

     

    39,930

     

     

     

    42,931

     

    Total shareholders’ equity

    $

    739,305

     

     

    $

    710,093

     

    Total liabilities and shareholders’ equity

    $

    2,209,570

     

     

    $

    2,190,863

     

    EVOQUA WATER TECHNOLOGIES CORP.

    CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS (Unaudited)

    (In thousands)

     

     

    Six Months Ended March 31,

     

     

    2023

     

     

     

    2022

     

    Operating activities

     

     

     

    Net income

    $

    19,900

     

     

    $

    13,462

     

    Reconciliation of net income to cash flows (used in) provided by operating activities:

     

     

     

    Depreciation and amortization

     

    66,647

     

     

     

    61,156

     

    Amortization of deferred financing fees

     

    943

     

     

     

    926

     

    Deferred income taxes

     

    3,195

     

     

     

    592

     

    Share-based compensation

     

    12,200

     

     

     

    10,589

     

    Gain on sale of property, plant and equipment

     

    (1,403

    )

     

     

    (61

    )

    Loss (gain) on sale of business

     

    2,857

     

     

     

    (193

    )

    Impairment of long-lived assets

     

    1,703

     

     

     

     

    Foreign currency exchange (gains) losses on intercompany loans and other non-cash items

     

    (9,805

    )

     

     

    3,728

     

    Changes in assets and liabilities

     

    (62,050

    )

     

     

    (61,051

    )

    Net cash provided by operating activities

     

    34,187

     

     

     

    29,148

     

    Investing activities

     

     

     

    Purchase of property, plant, and equipment

     

    (53,211

    )

     

     

    (36,320

    )

    Purchase of intangibles

     

    (2,479

    )

     

     

    (1,582

    )

    Proceeds from sale of property, plant, and equipment

     

    3,621

     

     

     

    1,940

     

    Proceeds from sale of business, net of cash of $0 and $0

     

    67

     

     

     

    356

     

    Acquisitions

     

    816

     

     

     

    (194,976

    )

    Net cash used in investing activities

     

    (51,186

    )

     

     

    (230,582

    )

    Financing activities

     

     

     

    Borrowing of debt

     

    157,774

     

     

     

    223,793

     

    Repayment of debt

     

    (166,542

    )

     

     

    (33,362

    )

    Repayment of finance lease obligation

     

    (7,156

    )

     

     

    (6,571

    )

    Receipt of earn-out related to previous acquisitions

     

    7,824

     

     

     

     

    Proceeds from issuance of common stock

     

    4,700

     

     

     

    5,274

     

    Taxes paid related to net share settlements of share-based compensation awards

     

    (4,734

    )

     

     

    (5,144

    )

    Distribution to non‑controlling interest

     

     

     

     

    (100

    )

    Net cash used in financing activities

     

    (8,134

    )

     

     

    183,890

     

    Effect of exchange rate changes on cash

     

    4,371

     

     

     

    800

     

    Change in cash and cash equivalents

     

    (20,762

    )

     

     

    (16,744

    )

    Cash and cash equivalents

     

     

     

    Beginning of period

     

    134,005

     

     

     

    146,244

     

    End of period

    $

    113,243

     

     

    $

    129,500

     

    Revenue

    Revenue is used by management to evaluate the performance of our business. Revenue growth is primarily related to organic and inorganic factors. Organic revenue growth, as a component of revenue growth, is defined as period over period revenue growth without (i) the impact from acquisitions and divestitures during the first 12 months following the closing of the acquisition or divestiture, which we refer to as inorganic impact, and (ii) the impact of foreign currency translation. Divestitures include sales of insignificant portions of our business that did not meet the criteria for classification as a discontinued operation. We disregard the effect of foreign currency translation from organic revenue growth because foreign currency translation is not under management’s control, is subject to volatility and can obscure underlying business trends. The effect of acquisitions and divestitures during the first 12 months following the closing of the acquisition or divestiture are excluded because they can obscure underlying business trends and make comparisons of long-term performance difficult between the Company and its peers due to the varying nature, size, and number of transactions from period to period.

    Components of our revenue growth for the three months ended March 31, 2023 and 2022 are as follows:

     

    Evoqua Water Technologies

     

    Integrated Solutions and Services

     

    Applied Product Technologies

    (In millions)

    $ Change

     

    % Change

     

    $ Change

     

    % Change

     

    $ Change

     

    % Change

    Three months ended March 31, 2021 total revenue

    $

    346.6

     

     

    n/a

     

     

    $

    224.2

     

     

    n/a

     

     

    $

    122.4

     

     

    n/a

     

    Organic

     

    36.7

     

     

    10.6

    %

     

     

    25.6

     

     

    11.4

    %

     

     

    11.1

     

     

    9.1

    %

    Inorganic

     

    45.1

     

     

    13.0

    %

     

     

    45.1

     

     

    20.1

    %

     

     

     

     

    %

    Foreign currency translation

     

    (1.7

    )

     

    (0.5

    )%

     

     

    (0.1

    )

     

    %

     

     

    (1.6

    )

     

    (1.3

    )%

    Three months ended March 31, 2022 total revenue

    $

    426.7

     

     

    23.1

    %

     

    $

    294.8

     

     

    31.5

    %

     

    $

    131.9

     

     

    7.8

    %

    Organic

     

    49.6

     

     

    11.6

    %

     

     

    29.6

     

     

    10.0

    %

     

     

    20.0

     

     

    15.2

    %

    Inorganic

     

    5.3

     

     

    1.2

    %

     

     

    5.3

     

     

    1.8

    %

     

     

     

     

    %

    Foreign currency translation

     

    (3.8

    )

     

    (0.8

    )%

     

     

    (0.8

    )

     

    (0.2

    )%

     

     

    (3.0

    )

     

    (2.3

    )%

    Three months ended March 31, 2023 total revenue

    $

    477.8

     

     

    12.0

    %

     

    $

    328.9

     

     

    11.6

    %

     

    $

    148.9

     

     

    12.9

    %

    Use of Non-GAAP Measures

    The Company reports its financial results in accordance with GAAP. However, management believes that certain non-GAAP financial measures provide users of the Company's financial information with additional useful information in evaluating operating performance. We use the non-GAAP financial measures EBITDA and adjusted EBITDA in evaluating the strength and financial performance of our core business.

    EBITDA and Adjusted EBITDA

    EBITDA, which is a non-GAAP financial measure, is defined as net income (loss) before interest expense, income tax benefit (expense), and depreciation and amortization. Adjusted EBITDA is defined as net income (loss) before interest expense, income tax benefit (expense), and depreciation and amortization, adjusted for the impact of certain other items, including restructuring and related business transformation costs, share-based compensation, transaction costs, and other gains, losses and expenses that we believe do not directly reflect our underlying business operations.

    Adjusted EBITDA is one of the primary metrics used by management to evaluate the financial performance of our business. We present adjusted EBITDA because we believe it is frequently used by analysts, investors and other interested parties to evaluate and compare operating performance and value companies within our industry. Further, we believe it is helpful in highlighting trends in our operating results and provides greater clarity and comparability period over period to management and our investors regarding the operational impact of long-term strategic decisions relating to capital structure, the tax jurisdictions in which we operate and capital investments. In addition, adjusted EBITDA highlights true business performance by removing the impact of certain items that management believes do not directly reflect our underlying operations and provides investors with greater visibility into the ongoing organic drivers of our business performance.

    Management uses adjusted EBITDA to supplement GAAP measures of performance as follows:

    • to assist investors and analysts in comparing our operating performance across reporting periods on a consistent basis by excluding items that we do not believe are indicative of our core operating performance;
    • in our management incentive compensation, which is based in part on components of adjusted EBITDA;
    • in certain calculations under our senior secured credit facilities, which use components of adjusted EBITDA;
    • to evaluate the effectiveness of our business strategies;
    • to make budgeting decisions; and
    • to compare our performance against that of other peer companies using similar measures.

    In addition to the above, our chief operating decision maker uses adjusted EBITDA of each reportable operating segment to evaluate the operating performance of such segments. Adjusted EBITDA on a segment basis is defined as earnings before depreciation and amortization, adjusted for the impact of certain other items that have been reflected at the segment level. Adjusted EBITDA of the reportable operating segments do not include certain charges that are presented within corporate activities. These charges include certain restructuring and other business transformation charges that have been incurred to align and reposition the Company to the current reporting structure, acquisition related costs (including transaction costs and integration costs) and share-based compensation charges.

    EBITDA and Adjusted EBITDA should not be considered a substitute for, or superior to, financial measures prepared in accordance with GAAP. The financial results prepared in accordance with GAAP and the reconciliations from these results included below should be carefully evaluated. You are encouraged to evaluate each adjustment and the reasons we consider it appropriate for supplemental analysis. In addition, in evaluating adjusted EBITDA, you should be aware that in the future, we may incur expenses similar to the adjustments in the presentation of adjusted EBITDA. Our presentation of adjusted EBITDA should not be construed as an inference that our future results will be unaffected by unusual or non-recurring items. In addition, other companies in our industry or across different industries may calculate adjusted EBITDA differently.

    The following is a reconciliation of our net income to EBITDA and adjusted EBITDA (unaudited):

     

    Three Months Ended

    March 31,

     

    Six Months Ended

    March 31,

    (In millions)

     

    2023

     

     

     

    2022

     

     

    Variance(1)

     

     

    2023

     

     

     

    2022

     

     

    Variance(1)

    Net income

    $

    10.6

     

     

    $

    7.4

     

     

    43.2

    %

     

    $

    19.9

     

     

    $

    13.5

     

     

    47.4

    %

    Income tax expense

     

    2.5

     

     

     

    2.2

     

     

    13.6

    %

     

     

    6.4

     

     

     

    3.9

     

     

    64.1

    %

    Interest expense

     

    10.3

     

     

     

    10.0

     

     

    3.0

    %

     

     

    20.4

     

     

     

    16.5

     

     

    23.6

    %

    Operating profit

    $

    23.4

     

     

    $

    19.6

     

     

    19.4

    %

     

    $

    46.7

     

     

    $

    33.9

     

     

    37.8

    %

    Depreciation and amortization

     

    33.4

     

     

     

    32.6

     

     

    2.5

    %

     

     

    66.6

     

     

     

    61.2

     

     

    8.8

    %

    EBITDA

    $

    56.8

     

     

    $

    52.2

     

     

    8.8

    %

     

    $

    113.3

     

     

    $

    95.1

     

     

    19.1

    %

    Restructuring and related business transformation costs(a)

     

    1.4

     

     

     

    1.8

     

     

    (22.2

    )%

     

     

    3.1

     

     

     

    3.2

     

     

    (3.1

    )%

    Purchase accounting adjustment costs(b)

     

     

     

     

    2.6

     

     

    (100.0

    )%

     

     

     

     

     

    2.6

     

     

    (100.0

    )%

    Share-based compensation(c)

     

    6.9

     

     

     

    6.1

     

     

    13.1

    %

     

     

    13.2

     

     

     

    11.4

     

     

    15.8

    %

    Transaction costs(d)

     

    18.0

     

     

     

    4.0

     

     

    350.0

    %

     

     

    21.3

     

     

     

    4.9

     

     

    334.7

    %

    Other losses (gains) and expenses(e)

     

    5.4

     

     

     

    6.5

     

     

    (16.9

    )%

     

     

    10.3

     

     

     

    10.3

     

     

    %

    Adjusted EBITDA

    $

    88.5

     

     

    $

    73.2

     

     

    20.9

    %

     

    $

    161.2

     

     

    $

    127.5

     

     

    26.4

    %

     

     

     

     

     

     

     

     

     

     

     

     

    Revenue

    $

    477.8

     

     

    $

    426.7

     

     

    12.0

    %

     

    $

    913.6

     

     

    $

    793.0

     

     

    15.2

    %

     

     

     

     

     

     

     

     

     

     

     

     

    Net income as a percent of revenue

     

    2.2

    %

     

     

    1.7

    %

     

    50 bps

     

     

    2.2

    %

     

     

    1.7

    %

     

    50 bps

    Adjusted EBITDA margin

     

    18.5

    %

     

     

    17.2

    %

     

    130 bps

     

     

    17.6

    %

     

     

    16.1

    %

     

    150 bps

    (a)

    Restructuring and related business transformation costs

     

     

     

    Adjusted EBITDA is calculated prior to considering certain restructuring or business transformation events. These events may occur over extended periods of time, and in some cases it is reasonably possible that they could reoccur in future periods based on reorganizations of the business, cost reduction or productivity improvement needs, or in response to economic conditions. For the periods presented such events include the following:

     

     

     

    (i) Certain costs and expenses in connection with various restructuring initiatives, including severance and other employee-related costs, relocation and facility consolidation costs and third-party consultant costs to assist with these initiatives. This includes:

     

     

     

    (A) amounts related to the Company’s restructuring initiatives to reduce the cost structure and rationalize location footprint;

     

     

    (B) amounts related to various other initiatives implemented to restructure and reorganize our business with the appropriate management team and cost structure.

     

     

     

    (ii) Legal settlement costs and intellectual property related fees, including fees and settlement costs associated with legacy matters related to product warranty litigation on MEMCOR products and certain discontinued products. Memcor is a trademark of Rohm & Haas Electronic Materials Singapore Pte. Ltd.

     

     

     

    (iii) Expenses associated with our information technology and functional infrastructure transformation, including activities to optimize information technology systems and functional infrastructure processes.

     

     

    (b)

    Purchase accounting adjustment costs

     

     

     

    Adjusted EBITDA is calculated prior to considering adjustments for the effect of the purchase accounting step-up in the value of inventory to fair value recognized in cost of goods sold as a result of the acquisition of the Mar Cor Business.

     

     

    (c)

    Share-based compensation

     

     

     

    Adjusted EBITDA is calculated prior to considering share-based compensation expenses related to equity awards. See Note 17, “Share-Based Compensation,” to our Unaudited Consolidated Financial Statements included in our Quarterly Report on Form 10-Q for the six months ended March 31, 2023 for further detail.

     

     

    (d)

    Transaction costs

     

     

     

    Adjusted EBITDA is calculated prior to considering transaction, integration and restructuring costs associated with business combinations because these costs are unique to each transaction and represent costs that were incurred as a result of the transaction decision. Integration and restructuring costs associated with a business combination may occur over several years and include, but are not limited to, consulting fees, legal fees, certain employee-related costs, facility consolidation and product rationalization costs and fair value changes associated with contingent consideration.

     

     

    (e)

    Other losses (gains) and expenses

     

     

     

    Adjusted EBITDA is calculated prior to considering certain other significant losses, (gains) and expenses. For the periods presented such events include the following:

     

     

     

    (i) impact of foreign exchange gains and losses; and

     

     

     

    (ii) legal fees and settlement costs incurred in excess of amounts covered by the Company’s insurance related to securities litigation and SEC investigation matters; and

     

     

     

    (iii) loss on sale of the Filtration Business within the Integrated Solutions and Services Segment; and

     

     

     

    (iv) impairment of certain long-lived assets related to product rationalization in the electro-chlorination business.

     

     

    (1)

    Variance presented as a percentage for items presented in dollar values or basis points (“bps”) for items presented as percentages.

     


    The Evoqua Water Technologies Stock at the time of publication of the news with a fall of -0,09 % to 45,34USD on Tradegate stock exchange (02. Mai 2023, 12:02 Uhr).


    Business Wire (engl.)
    0 Follower
    Autor folgen

    Evoqua Water Technologies Reports Second Quarter 2023 Results Evoqua Water Technologies (NYSE:AQUA), an industry leader in mission-critical water treatment solutions, today reported results for its second quarter ended March 31, 2023. Revenue for the second quarter of fiscal year 2023 was $477.8 million, …